secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2026-08-12T13:05:17+00:00
Accession:  0001193125-26-345874
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences Q2 2026: cash $96.3M, TA-ERT BLA on track for Q4, $5.5M investment
--------------------------------------------------------------------------------

- Cash and equivalents $96.3M at Jun 30, 2026 vs $48.9M at Dec 31, 2025; runway into H2 2027.
- Q2 2026 net loss $16.2M ($6.68/share); six-month net loss $28.5M ($14.96/share).
- BLA for TA-ERT (MPS IIIB) expected Q4 2026; TrAnsform confirmatory study to initiate Q4 2026.
- Cure Sanfilippo Foundation and National MPS Society invest combined $5.5M to fund TA-ERT Expanded Access Program.
- Appointed Adrian Quartel, M.D. as CMO (Jul 27, 2026) and Jessica Cohen Pfeffer, M.D. as VP Clinical Development (Aug 3, 2026).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000119312526345874/0001193125-26-345874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000119312526345874/sprb-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-345874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer